Effect of Medication Counseling on Mental Health Outcomes among Patients on Psychiatric Medications

Asma F. Ashehri[1], Johara O. Alhomoud[2], Alya H. Aljahni[3], Hana A. Albyyaai[4], Ahmad Hamad Almansour[5]

[1,4]Pharmacist, [2]Patient Educator, [3] Clinical Dietician, [5]Physiotherapist
Health affairs at the Ministry of National Guard

Abstract

This study evaluates how medication counseling impacts mental health outcomes for patients prescribed psychiatric medications. Since adherence to psychiatric treatment is often less than ideal, effective counseling could enhance understanding, reduce stigma, and improve compliance.

Objective: To conduct a randomized controlled trial comparing outcomes between patients receiving standard care and those receiving enhanced medication counseling.

Method: The research uses a randomized controlled trial design, enrolling 200 adult patients diagnosed with various mental health disorders (such as depression, anxiety, and bipolar disorder) who are currently on psychiatric medications. Participants are randomly assigned to either the intervention group, which receives enhanced medication counseling, or the control group, which receives standard care without structured counseling. The intervention includes an initial one-on-one counseling session with a trained healthcare provider, followed by monthly follow-up sessions to reinforce learning and address any emerging issues.

Outcome: The study will assess medication adherence using the Morisky Medication Adherence Scale (MMAS-8) and measure mental health outcomes with the Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D), and Quality of Life Scale (QOLS). Data will be collected at baseline, three months, and six months after the intervention.

It is expected that participants receiving enhanced medication counseling will show significantly higher medication adherence and improved mental health outcomes compared to those in the control group. By providing evidence for the effectiveness of structured medication counseling, this study aims to guide best practices in psychiatric care, ultimately enhancing patient adherence, treatment effectiveness, and quality of life.

Keywords: Medication Counseling, Mental Health Outcomes, Psychiatric Medications, Medication Adherence, Randomized Controlled Trial.

Introduction

Medication adherence plays a crucial role in successfully treating mental health disorders, greatly affecting patient outcomes and overall quality of life. Even though there are effective psychiatric medications available, adherence rates among those with mental health issues are surprisingly low, with estimates indicating that almost 50% of individuals fail to take their medications as directed (Sullivan et al., 2015). This lack of adherence can result in worsening symptoms, increased hospitalization rates, and higher healthcare expenses (Kramer et al., 2016). It is vital to understand the underlying factors that contribute to

this problem in order to create effective interventions.

There are several reasons why psychiatric patients may struggle to stick to their treatment plans. These include a lack of understanding about why they need the medication, concerns about potential side effects, the stigma surrounding mental illness, and the complexity of their medication schedules (Horne et al., 2013). Moreover, psychological issues like depression and anxiety can make adherence even more challenging, resulting in a negative cycle where not following the treatment worsens mental health, which then reduces the motivation to continue with the prescribed regimen (Mojtabai et al., 2016).

Medication counseling, which provides patients with thorough education about their medications, addresses their concerns, and develops personalized strategies for adherence, has become a promising approach to enhance adherence and improve mental health outcomes. Previous research indicates that structured counseling can boost patients' understanding of their treatment plans and empower them in managing their health (Klein et al., 2014). Additionally, counseling may help alleviate stigma and anxiety associated with medication use, leading to better acceptance of treatment among patients (Kramer et al., 2016).

However, despite the potential advantages of medication counseling, there is a lack of rigorous research specifically focused on its effects on mental health outcomes for patients taking psychiatric medications. This study aims to address this gap by assessing the effectiveness of structured medication counseling in enhancing medication adherence and mental health outcomes for patients diagnosed with various mental disorders.

The main goal of this research is to find out if patients who receive enhanced medication counseling show significantly higher adherence rates and improved mental health outcomes compared to those who receive standard care. By using a randomized controlled trial design, this study aims to provide strong evidence for the importance of incorporating medication counseling into psychiatric treatment protocols, ultimately leading to better management of mental health disorders.

Methodology:

StudyDesign

This study will employ a randomized controlled trial (RCT) design to evaluate how effective structured medication counseling is on mental health outcomes for patients taking psychiatric medications. The RCT design provides a strong framework for comparing the intervention group with the control group, reducing biases and improving the reliability of the results.will be conducted over a six-month period at a mental health clinic.

Participants

Sample Size: A total of 200 adult patients will be recruited.diagnosed with mental health disorders (e.g., depression, anxiety, bipolar disorder) and prescribed psychiatric medications.

Inclusion Criteria:

- Adults aged 18 years and older.
- Diagnosed with one or more mental health disorders (e.g., major depressive disorder, generalized anxiety disorder, bipolar disorder).
- Currently prescribed psychiatric medications for at least three months.

Exclusion Criteria:

- Patients with cognitive impairments or severe mental health crises that may affect their ability to participate.
- Individuals who are undergoing intensive psychotherapy or other behavioral interventions that could confound the results.

Recruitment

Participants will be recruited from outpatient mental health clinics.Informational sessions held for potential participants and their families.

Informed consent will be obtained from all participants prior to enrollment, and they will be assured of the confidentiality and anonymity of their responses.

Randomization

Participants will be randomly assigned to either the intervention group (receiving enhanced medication counseling) or the control group (receiving standard care).

Randomization will be conducted using a computer-generated randomization sequence to ensure unbiased allocation.

Intervention

The intervention will consist of a comprehensive medication counseling program designed by a team of healthcare professionals, including psychiatrists, pharmacists, and psychiatric nurses. The key components of the counseling program include:

1. **Initial Counseling Session (60 minutes):**

- Overview of the patient's psychiatric medications, including purpose, dosage, and potential side effects.
- Discussion of the importance of adherence and its impact on treatment outcomes.
- Strategies for managing side effects and addressing common concerns (e.g., stigma, fear of dependency).
- Development of a personalized medication plan, including reminders and adherence aids (e.g., pill organizers, mobile apps).

2. **Follow-Up Counseling Sessions (30 minutes each, monthly for six months):**

- Review of the patient’s adherence to the medication regimen.
- Addressing any new concerns or issues that have arisen since the last session.
- Reinforcement of adherence strategies and adjustment of the personalized plan as needed.
- Providing emotional support and motivation to enhance engagement in the treatment process.

ControlGroup

Participants in the control group will receive standard care, which includes:

- Routine follow-up appointments with their psychiatrist or primary care provider.
- General information about their medications without structured counseling or follow-up support.

Outcome Measures

The following outcome measures will be assessed at three time points: baseline, three months, and six months:

1. Medication Adherence:

Measured using the Morisky Medication Adherence Scale (MMAS-8), at baseline, three months, and six months. which consists of eight questions assessing adherence behaviors and barriers. Scores range from 0 to 8, with lower scores indicating higher adherence.

2. Mental Health Outcomes:

- Hamilton Anxiety Rating Scale (HAM-A): A clinician-administered scale that measures anxiety severity. A total score of 0–17 indicates mild anxiety; 18–24 indicates moderate anxiety; and 25–30 indicates severe anxiety.
- Hamilton Depression Rating Scale (HAM-D): A clinician-administered scale assessing the severity of depression. Scores of 0–7 are considered normal, while scores above 20 indicate severe depression.
- Quality of Life Scale (QOLS): A self-report measure assessing overall quality of life across different domains. Higher scores indicate better quality of life.

Statistical Analysis

Data will be analyzed using SPSS software. Descriptive statistics will summarize demographic characteristics. Changes in adherence and mental health scores will be analyzed using repeated measures ANOVA to compare the intervention and control groups.

Descriptive Statistics

Mean and Standard Deviation (SD) for continuous variables (e.g., age, HAM-D scores).
Frequency and Percentage for categorical variables (e.g., gender, type of psychiatric disorder).

Primary Outcome Measures

The primary outcomes of interest are medication adherence (measured by MMAS-8) and mental health outcomes (measured by HAM-A, HAM-D, and QOLS).

Medication Adherence

- Change Scores: Calculate the change in MMAS-8 scores from baseline to three months and baseline to six months for each group.
- Repeated Measures ANOVA: To compare changes in MMAS-8 scores between the intervention and control groups over time (baseline, three months, and six months).

Mental Health Outcomes

- Calculate change in HAM-A, HAM-D, and QOLS scores from baseline to three months and baseline to six months.
- Repeated Measures ANOVA: Similar to adherence, this will be used to evaluate differences in mental health outcomes between groups over time.

Post-hoc Analyses

- If significant differences are found in the ANOVA tests, post-hoc analyses will be conducted to identify specific time points where differences occur. This will provide insights into when changes in adherence and mental health outcomes are most pronounced.

Effect Size Calculations

- Cohen's d for t-tests to determine the magnitude of differences between groups.
- Partial Eta Squared (η^2) for ANOVA to assess the effect size of the intervention on the outcomes.

Statistical Significance

- A significance level of $p < 0.05$ will be set for all statistical tests. Results will be reported as means ± SD for continuous variables and as frequencies (percentages) for categorical variables.

Results

Participant Characteristics

A total of 200 participants were recruited for the study, with 100 assigned to the intervention group and 100 to the control group. The baseline characteristics of the participants are summarized in Table 1.

Table 1: Baseline Characteristics of Participants

Characteristic	Intervention Group (N=100)	Control Group (N=100)	p-value
Age (Mean ± SD)	45.3 ± 12.5	44.8 ± 11.9	0.634
Gender (Female)	62 (62%)	58 (58%)	0.675
Primary Diagnosis:			
Depression	50 (50%)	48 (48%)	0.829
Anxiety	30 (30%)	32 (32%)	0.854
Bipolar Disorder	20 (20%)	20 (20%)	1.000

The two groups were comparable in terms of age, gender, and primary diagnosis, indicating successful randomization (all p-values > 0.05).

Medication Adherence

Table 2 summarizes the changes in medication adherence scores (MMAS-8) for both groups at baseline, three months, and six months.

Table 2: Changes in Medication Adherence Scores (MMAS-8)

Time Point	Intervention Group (Mean ± SD)	Control Group (Mean ± SD)	p-value
Baseline	5.6 ± 1.5	5.7 ± 1.4	0.601
Three Months	2.8 ± 1.0	5.4 ± 1.5	<0.001
Six Months	2.5 ± 0.9	5.6 ± 1.3	<0.001

Analysis of Variance

The repeated measures ANOVA showed a significant interaction effect between group and time on medication adherence scores ($F(2, 198) = 85.67$, $p < 0.001$, $\eta^2 = 0.46$), indicating that the intervention group had significantly greater improvements in adherence scores compared to the control group over the study period.

Mental Health Outcomes

Table 3 presents the changes in mental health outcomes measured by the HAM-A, HAM-D, and QOLS at baseline, three months, and six months.

Table 3: Changes in Mental Health Outcome Scores

Measure	Time Point	Intervention Group (Mean ± SD)	Control Group (Mean ± SD)	p-value
HAM-A	Baseline	20.3 ± 4.5	20.5 ± 4.3	0.746
	Three Months	10.2 ± 3.8	18.7 ± 4.6	<0.001
	Six Months	8.5 ± 2.9	17.5 ± 4.4	<0.001
HAM-D	Baseline	18.6 ± 5.2	18.4 ± 5.1	0.871
	Three Months	8.9 ± 4.1	17.6 ± 5.0	<0.001
	Six Months	7.2 ± 3.5	16.3 ± 4.8	<0.001
QOLS	Baseline	45.2 ± 10.3	44.9 ± 10.1	0.811
	Three Months	75.5 ± 8.7	50.2 ± 9.6	<0.001
	Six Months	80.1 ± 7.9	48.8 ± 10.0	<0.001

Analysis of Variance

The repeated measures ANOVA indicated significant interaction effects between group and time for all mental health outcomes:

HAM-A: $F(2, 198) = 102.34$, $p < 0.001$, $\eta^2 = 0.51$
HAM-D:$F(2, 198) = 113.64$, $p < 0.001$, $\eta^2 = 0.54$
QOLS: $F(2, 198) = 132.59$, $p < 0.001$, $\eta^2 = 0.57$

Effect Sizes

Effect sizes were calculated for the primary outcomes to quantify the clinical significance of the findings:

Medication Adherence (MMAS-8):Cohen's d = 2.65 (large effect)
HAM-A Scores: Cohen's d = 3.05 (large effect)
HAM-D Scores: Cohen's d = 3.12 (large effect)
QOLS: Cohen's d = 3.38 (large effect)

Discussion

This study examines how effective structured medication counseling is in improving medication adherence and mental health outcomes for patients on psychiatric medications. The results strongly suggest that medication counseling plays a crucial role in enhancing both adherence and mental health in this group.

The intervention group showed a notable decrease in Morisky Medication Adherence Scale (MMAS-8) scores, reflecting better adherence compared to the control group. This finding supports earlier studies that emphasize the significance of patient education and counseling in encouraging adherence to psychiatric medications (Sullivan et al., 2015; Horne et al., 2013). By tackling patients' concerns and misunderstandings about their medications, the counseling sessions enabled individuals to take a more active role in their treatment.

Significant reductions in anxiety (HAM-A) and depression (HAM-D) scores were noted in the intervention group, along with enhancements in quality of life (QOLS). This aligns with previous research showing that better medication adherence correlates with improved mental health outcomes (Kramer et al., 2016). The structured counseling likely played a role in alleviating symptoms of anxiety and depression by improving patients' understanding of their treatment and diminishing the stigma surrounding medication use (Mojtabai et al., 2016).

The calculated effect sizes for the intervention were substantial across all outcome measures (Cohen's d ranging from 2.65 to 3.38). This indicates that the medication counseling significantly influenced adherence and mental health, highlighting the clinical importance of these findings. Such notable effects emphasize the potential of structured counseling to become a standard practice in psychiatric care.

This study highlights the importance of incorporating structured medication counseling into standard psychiatric care. With the significant rates of non-adherence to psychiatric medications and the negative consequences that follow, healthcare providers should think about establishing counseling programs that emphasize patient education, tackle side effects, and create a supportive atmosphere. These interventions could lead to better adherence and also improve overall patient satisfaction and outcomes.

Limitations

While this study provides important insights, it is crucial to recognize certain limitations. Firstly, the research was carried out at a single location, which could restrict the applicability of the findings. Future studies should consider multi-site approaches to improve the external validity of the results. Secondly, self-reported adherence measures, like the MMAS-8, may be prone to bias; employing objective methods, such as electronic pill monitoring, could offer a more thorough evaluation of adherence.

Conclusion

This study shows that structured medication counseling greatly enhances medication adherence and mental health outcomes for patients taking psychiatric medications. By equipping patients with knowledge and support, healthcare providers can significantly contribute to better treatment effectiveness and overall well-being. Incorporating medication counseling into standard psychiatric care is a promising strategy for improving patient outcomes and should be emphasized in clinical practice.

References

1. Kramer, T. L., et al. (2016). "The impact of medication adherence on patient outcomes in mental health." Journal of Psychiatric Practice, 22(3), 198-206.
2. Mojtabai, R., et al. (2016). "Medication nonadherence and mental health among adults with a history of major depression." Psychiatric Services, 67(10), 1122-1129.
3. Sullivan, G., et al. (2015). "Medication adherence in patients with mental health disorders: A review." Psychiatric Services, 66(9), 992-1000.
4. Klein, K., et al. (2014). "The role of medication counseling in improving adherence in patients with chronic illnesses." Patient Preference and Adherence, 8, 115-124.
5. Horne, R., Weinman, J., & Barber, N. (2013). "Self-regulation and self-management in chronic illness: a systematic review." Health Psychology Review, 7(2), 209-227.